Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

BMC Gastroenterology

Nicola Balato²  Fabio Ayala²  Nicola Caporaso¹  Luisa Di Costanzo²  Serena La Bella²  Maria Guarino¹  Filomena Morisco¹ 

[1] Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Naples “Federico II”, Via S. Pansini, 5, Naples 80131, Italy;Dermatology Units, University of Naples “Federico II”, Via S. Pansini, 5, Naples 80131, Italy

关键词: Psoriasis;    Lamivudine;    Immunosuppressive therapy;    HCV infection;    HBV reactivation;    Biological drugs;   

Others  :  1121730
DOI  :  10.1186/s12876-014-0214-x

 received in 2014-09-09, accepted in 2014-12-09,  发布年份 2014

【 摘 要 】

Background

HBV and HCV reactivation have been widely reported in patients undergoing immunosuppressive therapy (IT); however, few data are available on the risk of reactivation in patients with psoriasis receiving IT. The aim of our study was to assess the prevalence of HBV and HCV infection in patients with psoriasis and to evaluate the effects of IT during the course of the infection.

Methods

The study included psoriatic patients who attended an Italian tertiary referral hospital from 2009 to 2012. A total of 224 patients were enrolled. We evaluated: HBV and HCV markers, type of IT and the occurrence of viral reactivation. The observational period ranged from the beginning of IT to the last visit, with a mean follow-up period of 54 months.

Results

Two hundred and twenty patients (135 males and 89 females; mean age 59 years; range 18–86 years) with psoriasis, with or without psoriatic arthritis, receiving conventional IT and/or biological drugs were tested for markers of infection. We identified 23/224 patients (10.2%) with isolated positivity for HBcAb positivity, 36/224 (16%) with positivity for HBsAb/HBcAb, and 15/224 (6.6%) with positivity for HCV-Ab. No patient was HBsAg positive, none of them underwent pre-emptive therapy with lamivudine or other antiviral drugs and no one showed episodes of viral reactivation.

Conclusions

The prevalence of HBsAg in patients with psoriasis is lower than that observed in the general population. The prevalence of isolated positivity for HBcAb and of combined positivity for HBcAb and HBsAb is 10.2% and 16%, respectively. The prevalence of HCV infection (HCV-RNA+) is 4%. In patients with psoriasis and HCV-Ab or HBcAb positivity, the IT seems to be safe, regardless of the type of drugs.

【 授权许可】

   
2014 Morisco et al.; licensee BioMed Central.

【 参考文献 】

• [1]Schon MP, Boehncke WH: Psoriasis. N Engl J Med 2005, 352(18):1899-1912.
• [2]Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004, 3(2):121-128.
• [3]Kivelevitch DN, Hebeler KR, Patel M, Menter A: Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs 2013, 18(4):523-532.
• [4]Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M: Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol 2012, 2012:747204.
• [5]Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, Ferrándiz C, Puig L, Sánchez-Carazo JL: Working Group on Comorbidity in Psoriasis: Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013, 27(11):1387-1404. doi:10.1111/jdv.12024
• [6]Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P: Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for haematological malignancies. Transplantation 2006, 82(1):141-142.
• [7]Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F: Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014, 20(13):3516-3524.
• [8]Liang R, Lau G, Kwong Y: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17(1):394-398.
• [9]Persico M, De Marino F, Di Giacomo Russo G, Morante A, Rotoli B, Torella R, De Renzo A: Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99(2):724-725.
• [10]Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344(1):68-69.
• [11]Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, Baldelli F: Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010, 38(1):58-61.
• [12]Yağci M, Ozkurt Z, Yeğin Z, Aki Z, Sucak GT, Haznedar R: Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010, 15(4):240-244.
• [13]Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M: Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011, 83(3):412-418.
• [14]Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. J Haematol 2003, 88(11):1296-1303.
• [15]Huang Y, Lin H, Lee S: Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc 2012, 75(8):359-362.
• [16]Lee I, Huang Y, Chu C, Lee PC, Lin HC, Lee SD: Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010, 73(3):156-160.
• [17]Hui C, Cheung W, Zhang H, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131(1):59-68.
• [18]Wu J, Huang Y, Lee P, Lin HC, Lee SD: Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 2009, 43(5):496-498.
• [19]Koskinas J, Tampaki M, Doumba PP, Rallis E: Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 2013, 168(3):679-680.
• [20]Fotiadou C, Lazaridou E, Ioannides D: Safety of anti-tumour necrosis factor- agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. JEADV 2011, 25(4):471-474.
• [21]Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R: Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995, 108(5):1453-1463.
• [22]Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA: Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011, 25(2):285-289.
• [23]Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T: Tumour necrosis factor-a antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011, 164(3):645-647.
• [24]Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E: Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013, 168(3):609-616.
• [25]Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF: The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C. Br J Dermatol 2013, 169(6):1295-1303.
• [26]Navarro R, Concha-Garzon MJ, Castano C, Casal C, Guiu A, Daudén E: Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Intern J Dermatol 2014, 65:1241-1245.
• [27]Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R: Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014, 33(2):273-276.
• [28]Navarro R, Concha-Garzón MJ, Castaño C, Casal C, Guiu A, Daudén E. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol. 2014 Feb 14. doi:10.1111/ijd.12313. [Epub ahead of print]
• [29]European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 2012, 57:167-185.
• [30]European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 2014, 60(2):392-420.
• [31]Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014, 14:31. BioMed Central Full Text
• [32]Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N: Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013, 20(3):200-208.
• [33]Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L: Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol 2012, 41(6):490-491.
• [34]Núñez-Rodríguez MH, Santamaría-Martínez A, Mata-Román L, Caro-Patón A: Reactivation of hepatitis B treated with adefovir after infliximab administration. Med Clin (Barc) 2006, 126(14):558-559.
• [35]Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M: BIOGEAS Study Group: Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011, 90(6):359-371.
• [36]Dernis E, Lavie F, Salliot C, Flipo RM, Saraux A, Maillefert JF, Paul C, Goupille P, Cantagrel A, Claudepierre P, Gaudin P, Tebib J, Wendling D, Schaeverbeke T, Le Loët X, Combe B: Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine 2009, 76(5):524-531.
• [37]Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British Association of Dermatologists: British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005, 153(3):486-497.
• [38]Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, Komine M, Etoh T, Igarashi A, Torii H, Asahina A, Nemoto O, Nakagawa H: Biologics Review Committee of the Japanese Dermatological Association: Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013, 40(9):683-695.